ArticleCancers2023
Immune Checkpoint Inhibitors in Cancer Therapy-How Can We Improve Clinical Benefits?
Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- The Immune Checkpoint Inhibitors Journey: From Early Promise to Lasting Impact.Journal of immunotherapy and precision oncology · 2026Review
- A Case Series of Raynaud's Phenomenon in the Setting of Immune Checkpoint Inhibitors.Journal of immunotherapy and precision oncology · 2026Article
- Advancing precision medicine: Uncovering biomarkers and strategies to mitigate immune-related adverse events in immune checkpoint inhibitors therapy.Toxicology reports · 2025Article
- Next-Generation Immunotherapy: Advancing Clinical Applications in Cancer Treatment.Journal of clinical medicine · 2024Article
- TGF-β trap of AdAPT-001 turns up the heat on tumors and turns down checkpoint blocker resistance.Journal for immunotherapy of cancer · 2024Article
- Systematic Review on the Effectiveness and Outcomes of Nivolumab Treatment Schemes in Advanced and Metastatic Cervical Cancer.Diseases (Basel, Switzerland) · 2024Review
- Perimyocarditis Associated with Immune Checkpoint Inhibitors: A Case Report and Review of the Literature.Medicina (Kaunas, Lithuania) · 2024Review
- Tolerated Re-Challenge of Immunotherapy in a Patient with ICI Associated Myocarditis: A Case Report and Literature Review.Medicina (Kaunas, Lithuania) · 2023Review
- Prospects for the Use of Metal-Based Nanoparticles as Adjuvants for Local Cancer Immunotherapy.Pharmaceutics · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors (ICIs) are in the spotlight of cancer treatment by increasing the probability for long-term survival in patients with metastatic disease and by considerably prolonging progression-free survival in patients at early disease stages [...].
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.